# B Paul Morgan

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9132592/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 504 papers | 30,387 citations | 3668 92 h-index | 10679 143 g-index |
| 523 all docs | 523 docs citations | 523 times ranked | 22260 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Development, Characterization, and in vivo Validation of a Humanized C6 Monoclonal Antibody that Inhibits the Membrane Attack Complex. Journal of Innate Immunity, 2023, 15, 16-36. | 1.8 | 2 |
| 2 | The Role of the Long-Term Acute Care Hospital Following Critical Illnessâ€"Has the Coronavirus Disease 2019 Pandemic Demonstrated Their Usefulness or Emphasized Their Downside?*. Critical Care Medicine, 2022, 50, 341-343. | 0.4 | 0 |
| 3 | Complement C3 and C3aR mediate different aspects of emotional behaviours; relevance to risk for psychiatric disorder. Brain, Behavior, and Immunity, 2022, 99, 70-82. | 2.0 | 11 |
| 4 | Whole bloodâ€based measurement of SARSâ€CoVâ€2â€specific T cells reveals asymptomatic infection and vaccine immunogenicity in healthy subjects and patients with solidâ€organ cancers. Immunology, 2022, 165, 250-259. | 2.0 | 21 |
| 5 | The association between neurodegeneration and local complement activation in the thalamus to progressive multiple sclerosis outcome. Brain Pathology, 2022, 32, e13054. | 2.1 | 13 |
| 6 | Targeting complement in neurodegeneration: challenges, risks, and strategies. Trends in Pharmacological Sciences, 2022, 43, 615-628. | 4.0 | 15 |
| 7 | C5b-9 Membrane Attack Complex Formation andÂExtracellular Vesicle Shedding in Barrettâ€™s Esophagus and Esophageal Adenocarcinoma. Frontiers in Immunology, 2022, 13, 842023. | 2.2 | 4 |
| 8 | Analysis of Complement Gene Expression, Clinical Associations, and Biodistribution of Complement Proteins in the Synovium of Early Rheumatoid Arthritis Patients Reveals Unique Pathophysiologic Features. Journal of Immunology, 2022, 208, 2482-2496. | 0.4 | 9 |
| 9 | Terminal complement pathway activation drives synaptic loss in Alzheimerâ€™s disease models. Acta Neuropathologica Communications, 2022, 10, . | 2.4 | 19 |
| 10 | Sepsis target validation for repurposing and combining complement and immune checkpoint inhibition therapeutics. Expert Opinion on Drug Discovery, 2021, 16, 537-551. | 2.5 | 6 |
| 11 | Role of complement and potential of complement inhibitors in myasthenia gravis and neuromyelitis optica spectrum disorders: a brief review. Journal of Neurology, 2021, 268, 1643-1664. | 1.8 | 18 |
| 12 | The Impact of Complement Genes on the Risk of Late-Onset Alzheimerâ€™s Disease. Genes, 2021, 12, 443. | 1.0 | 18 |
| 13 | The rareC9P167S risk variant for age-related macular degeneration increases polymerization of the terminal component of the complement cascade. Human Molecular Genetics, 2021, 30, 1188-1199. | 1.4 | 14 |
| 14 | Peripheral immune markers and antipsychotic non-response in psychosis. Schizophrenia Research, 2021, 230, 1-8. | 1.1 | 29 |
| 15 | Novel Monoclonal Antibodies Against Mouse C1q: Characterisation and Development of a Quantitative ELISA for Mouse C1q. Molecular Neurobiology, 2021, 58, 4323-4336. | 1.9 | 4 |
| 16 | Professor Sir Peter J. Lachmann, FRS, FMedSci (1931â€"2020). Viruses, 2021, 13, 1012. | 1.5 | 1 |
| 17 | Development of EndoScreen Chip, a Microfluidic Pre-Endoscopy Triage Test for Esophageal Adenocarcinoma. Cancers, 2021, 13, 2865. | 1.7 | 4 |
| 18 | C3 Glomerulopathy and Related Disorders in Children. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1639-1651. | 2.2 | 12 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Dissociable effects of complement C3 and C3aR on survival and morphology of adult born hippocampal neurons, pattern separation, and cognitive flexibility in male mice. Brain, Behavior, and Immunity, 2021, 98, 136-150. | 2.0 | 7 |
| 20 | Temporal development and neutralising potential of antibodies against SARS-CoV-2 in hospitalised COVID-19 patients: An observational cohort study. PLoS ONE, 2021, 16, e0245382. | 1.1 | 14 |
| 21 | The Use of Different Sepsis Risk Stratification Tools on the Wards and in Emergency Departments Uncovers Different Mortality Risks: Results of the Three Welsh National Multicenter Point-Prevalence Studies. , 2021, 3, e0558. | | 1 |
| 22 | Genetic Insights into the Impact of Complement in Alzheimerâ€™s Disease. Genes, 2021, 12, 1990. | 1.0 | 14 |
| 23 | Cerebrospinal fluid complement system biomarkers in demyelinating disease. Multiple Sclerosis Journal, 2020, 26, 1929-1937. | 1.4 | 22 |
| 24 | Role of the Complement Pathway in Inflammatory Skin Diseases: A Focus on Hidradenitis Suppurativa. Journal of Investigative Dermatology, 2020, 140, 531-536.e1. | 0.3 | 28 |
| 25 | Complement C5 Contributes to Brain Injury After Subarachnoid Hemorrhage. Translational Stroke Research, 2020, 11, 678-688. | 2.3 | 24 |
| 26 | Research priorities for the COVIDâ€19 pandemic and beyond: A call to action for psychological science. British Journal of Psychology, 2020, 111, 603-629. | 1.2 | 146 |
| 27 | Complement Inhibition with the C5 Blocker LFG316 in Severe COVID-19. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 1304-1308. | 2.5 | 45 |
| 28 | A novel mouse model expressing human forms for complement receptors CR1 and CR2. BMC Genetics, 2020, 21, 101. | 2.7 | 7 |
| 29 | Monoclonal Antibodies Capable of Inhibiting Complement Downstream of C5 in Multiple Species. Frontiers in Immunology, 2020, 11, 612402. | 2.2 | 16 |
| 30 | Retinal ganglion cell degeneration correlates with hippocampal spine loss in experimental Alzheimerâ€™s disease. Acta Neuropathologica Communications, 2020, 8, 216. | 2.4 | 24 |
| 31 | Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimerâ€™s Disease Multimodal Biomarker Discovery Cohort. Journal of Alzheimer's Disease, 2020, 74, 213-225. | 1.2 | 13 |
| 32 | Characterizing the original antiâ€C5 functionâ€blocking antibody, BB5.1, for species specificity, mode of action and interactions with C5. Immunology, 2020, 161, 103-113. | 2.0 | 11 |
| 33 | Increased circulating levels of Factor H-Related Protein 4 are strongly associated with age-related macular degeneration. Nature Communications, 2020, 11, 778. | 5.8 | 74 |
| 34 | Baseline high levels of complement component 4 predict worse clinical outcome at 1-year follow-up in first-episode psychosis. Brain, Behavior, and Immunity, 2020, 88, 913-915. | 2.0 | 25 |
| 35 | Complement factor I deficiency. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, . | 3.1 | 13 |
| 36 | An â€œOutside-Inâ€•and â€œInside-Outâ€•Consideration of Complement in the Multiple Sclerosis Brain: Lessons From Development and Neurodegenerative Diseases. Frontiers in Cellular Neuroscience, 2020, 14, 600656. | 1.8 | 28 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Complement factor C5 inhibition reduces type 2 responses without affecting group 2 innate lymphoid cells in a house dust mite induced murine asthma model. Respiratory Research, 2019, 20, 165. | 1.4 | 11 |
| 38 | Compendium of current complement therapeutics. Molecular Immunology, 2019, 114, 341-352. | 1.0 | 110 |
| 39 | Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay. Alzheimer's and Dementia, 2019, 15, 1478-1488. | 0.4 | 46 |
| 40 | Enhancing care of patients requiring a tracheostomy: A sustained quality improvement project. Journal of Critical Care, 2019, 54, 191-196. | 1.0 | 8 |
| 41 | â€˜Stealthâ€™ corporate innovation: an emerging threat for therapeutic drug development. Nature Immunology, 2019, 20, 1409-1413. | 7.0 | 7 |
| 42 | Development and characterization of novel antiâ€C5 monoclonal antibodies capable of inhibiting complement in multiple species. Immunology, 2019, 157, 283-295. | 2.0 | 20 |
| 43 | Inflammatory biomarkers in Alzheimer's disease plasma. Alzheimer's and Dementia, 2019, 15, 776-787. | 0.4 | 134 |
| 44 | C5b9 Deposition in Glomerular Capillaries Is Associated With Poor Kidney Allograft Survival in Antibody-Mediated Rejection. Frontiers in Immunology, 2019, 10, 235. | 2.2 | 14 |
| 45 | Therapeutic Inhibition of the Complement System in Diseases of the Central Nervous System. Frontiers in Immunology, 2019, 10, 362. | 2.2 | 148 |
| 46 | Sepsis: getting the balance right. BMJ, The, 2019, 367, l6700. | 3.0 | 7 |
| 47 | Measurement of soluble CD59 in CSF in demyelinating disease: Evidence for an intrathecal source of soluble CD59. Multiple Sclerosis Journal, 2019, 25, 523-531. | 1.4 | 9 |
| 48 | Complement system biomarkers in first episode psychosis. Schizophrenia Research, 2019, 204, 16-22. | 1.1 | 53 |
| 49 | Complement as a Mediator of Inflammation. , 2018, , 51-78. | | 0 |
| 50 | Introduction to complement in health and disease: novel aspects and insights. Seminars in Immunopathology, 2018, 40, 1-2. | 2.8 | 10 |
| 51 | Tissue microarray methodology identifies complement pathway activation and dysregulation in progressive multiple sclerosis. Brain Pathology, 2018, 28, 507-520. | 2.1 | 31 |
| 52 | Absence of CD59 in Guinea Pigs: Analysis of the Cavia porcellus Genome Suggests the Evolution of a CD59 Pseudogene. Journal of Immunology, 2018, 200, 327-335. | 0.4 | 4 |
| 53 | Complement in the pathogenesis of Alzheimerâ€™s disease. Seminars in Immunopathology, 2018, 40, 113-124. | 2.8 | 146 |
| 54 | Molecular pathogenesis of human CD59 deficiency. Neurology: Genetics, 2018, 4, e280. | 0.9 | 17 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Red-flag sepsis and SOFA identifies different patient population at risk of sepsis-related deaths on the general ward. Medicine (United States), 2018, 97, e13238. | 0.4 | 22 |
| 56 | CryoEM reveals how the complement membrane attack complex ruptures lipid bilayers. Nature Communications, 2018, 9, 5316. | 5.8 | 83 |
| 57 | Extracting the barbs from complement assays: Identification and optimisation of a safe substitute for traditional buffers. Immunobiology, 2018, 223, 744-749. | 0.8 | 15 |
| 58 | Complement system biomarkers in epilepsy. Seizure: the Journal of the British Epilepsy Association, 2018, 60, 1-7. | 0.9 | 32 |
| 59 | C9. , 2018, , 231-237. | | 1 |
| 60 | CD59. , 2018, , 361-367. | | 0 |
| 61 | Specific Inhibition of Complement Activation Significantly Ameliorates Autoimmune Blistering Disease in Mice. Frontiers in Immunology, 2018, 9, 535. | 2.2 | 29 |
| 62 | Characterizing a pHâ€switch antiâ€C5 antibody as a tool for human and mouse complement C5 purification and crossâ€species inhibition of classical and reactive lysis. Immunology, 2018, 155, 396-403. | 2.0 | 14 |
| 63 | We need a review of all sepsis deaths, not the conviction of health professionals. BMJ: British Medical Journal, 2018, 360, k629. | 2.4 | 1 |
| 64 | Systemic inhibition of the membrane attack complex impedes neuroinflammation in chronic relapsing experimental autoimmune encephalomyelitis. Acta Neuropathologica Communications, 2018, 6, 36. | 2.4 | 39 |
| 65 | CD93 regulates central nervous system inflammation in two mouse models of autoimmune encephalomyelitis. Immunology, 2018, 155, 346-355. | 2.0 | 29 |
| 66 | Hexamerization-enhanced CD20 antibody mediates complement-dependent cytotoxicity in serum genetically deficient in C9. Clinical Immunology, 2017, 181, 24-28. | 1.4 | 11 |
| 67 | The Correlation between Inflammatory Biomarkers and Polygenic Risk Score inÂAlzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2017, 56, 25-36. | 1.2 | 51 |
| 68 | Molecular cell biology of complement membrane attack. Seminars in Cell and Developmental Biology, 2017, 72, 124-132. | 2.3 | 85 |
| 69 | Plasma complement biomarkers distinguish multiple sclerosis and neuromyelitis optica spectrum disorder. Multiple Sclerosis Journal, 2017, 23, 946-955. | 1.4 | 42 |
| 70 | Microbial Neuraminidase Induces a Moderate and Transient Myelin Vacuolation Independent of Complement System Activation. Frontiers in Neurology, 2017, 8, 78. | 1.1 | 3 |
| 71 | Effects of freezer storage time on levels of complement biomarkers. BMC Research Notes, 2017, 10, 559. | 0.6 | 15 |
| 72 | High Levels of Soluble C5b-9 Complex in Dialysis Fluid May Predict Poor Prognosis in Peritonitis in Peritoneal Dialysis Patients. PLoS ONE, 2017, 12, e0169111. | 1.1 | 15 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Complement Membrane Attack and Tumorigenesis. Journal of Biological Chemistry, 2016, 291, 14927-14938. | 1.6 | 24 |
| 74 | Complement Biomarkers as Predictors of Disease Progression in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2016, 54, 707-716. | 1.2 | 41 |
| 75 | Inhibition of the classical pathway of the complement cascade prevents early dendritic and synaptic degeneration in glaucoma. Molecular Neurodegeneration, 2016, 11, 26. | 4.4 | 145 |
| 76 | Complementing the inflammasome. Immunology, 2016, 147, 152-164. | 2.0 | 55 |
| 77 | Thrombomodulin enhances complement regulation through strong affinity interactions with factor H and C3b-Factor H complex. Thrombosis Research, 2016, 145, 84-92. | 0.8 | 25 |
| 78 | Structural basis of complement membrane attack complex formation. Nature Communications, 2016, 7, 10587. | 5.8 | 213 |
| 79 | Terminal complexes of the complement system: new structural insights and their relevance to function. Immunological Reviews, 2016, 274, 141-151. | 2.8 | 57 |
| 80 | Complement system activation contributes to the ependymal damage induced by microbial neuraminidase. Journal of Neuroinflammation, 2016, 13, 115. | 3.1 | 9 |
| 81 | Complement activation in leprosy: a retrospective study shows elevated circulating terminal complement complex in reactional leprosy. Clinical and Experimental Immunology, 2016, 184, 338-346. | 1.1 | 8 |
| 82 | Editorial. Immunobiology, 2016, 221, 699-700. | 0.8 | 0 |
| 83 | Complement is activated in progressive multiple sclerosis cortical grey matter lesions. Journal of Neuroinflammation, 2016, 13, 161. | 3.1 | 101 |
| 84 | Complement and Humoral Adaptive Immunity in the Human Choroid Plexus: Roles for Stromal Concretions, Basement Membranes, and Epithelium. Journal of Neuropathology and Experimental Neurology, 2016, 75, 415-428. | 0.9 | 13 |
| 85 | Genetic analysis and functional characterization of novel mutations in a series of patients with atypical hemolytic uremic syndrome. Molecular Immunology, 2016, 71, 10-22. | 1.0 | 27 |
| 86 | Deletion of the membrane complement inhibitor CD59a drives age and gender-dependent alterations to bone phenotype in mice. Bone, 2016, 84, 253-261. | 1.4 | 18 |
| 87 | A De Novo Deletion in the Regulators of Complement Activation Cluster Producing a Hybrid Complement Factor H/Complement Factor Hâ€“Related 3 Gene in Atypical Hemolytic Uremic Syndrome. Journal of the American Society of Nephrology: JASN, 2016, 27, 1617-1624. | 3.0 | 34 |
| 88 | The membrane attack complex as an inflammatory trigger. Immunobiology, 2016, 221, 747-751. | 0.8 | 173 |
| 89 | Complement activation and expression during chronic relapsing experimental autoimmune encephalomyelitis in the Biozzi ABH mouse. Clinical and Experimental Immunology, 2015, 180, 432-441. | 1.1 | 8 |
| 90 | Adjuvant treatment with dexamethasone plus anti-C5 antibodies improves outcome of experimental pneumococcal meningitis: a randomized controlled trial. Journal of Neuroinflammation, 2015, 12, 149. | 3.1 | 26 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Thrombinâ€activatable fibrinolysis inhibitor influences disease severity in humans and mice with pneumococcal meningitis. Journal of Thrombosis and Haemostasis, 2015, 13, 2076-2086. | 1.9 | 12 |
| 92 | Response to Comment on â€œFunctional Analysis of a Complement Polymorphism (rs17611) Associated with Rheumatoid Arthritisâ€. Journal of Immunology, 2015, 195, 4-4. | 0.4 | 2 |
| 93 | An anticomplement agent that homes to the damaged brain and promotes recovery after traumatic brain injury in mice. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 14319-14324. | 3.3 | 67 |
| 94 | A complement C5 gene mutation, c.754G>A:p.A252T, is common in the Western Cape, South Africa and found to be homozygous in seven percent of Black African meningococcal disease cases. Molecular Immunology, 2015, 64, 170-176. | 1.0 | 20 |
| 95 | M. leprae components induce nerve damage by complement activation: identification of lipoarabinomannan as the dominant complement activator. Acta Neuropathologica, 2015, 129, 653-667. | 3.9 | 36 |
| 96 | Functional Analysis of a Complement Polymorphism (rs17611) Associated with Rheumatoid Arthritis. Journal of Immunology, 2015, 194, 3029-3034. | 0.4 | 33 |
| 97 | The molecular and structural bases for the association of complement C3 mutations with atypical hemolytic uremic syndrome. Molecular Immunology, 2015, 66, 263-273. | 1.0 | 47 |
| 98 | The role of complement in neurological and neuropsychiatric diseases. Expert Review of Clinical Immunology, 2015, 11, 1109-1119. | 1.3 | 31 |
| 99 | Complement, a target for therapy in inflammatory and degenerative diseases. Nature Reviews Drug Discovery, 2015, 14, 857-877. | 21.5 | 357 |
| 100 | A Novel Antibody against Human Factor B that Blocks Formation of the C3bB Proconvertase and Inhibits Complement Activation in Disease Models. Journal of Immunology, 2014, 193, 5567-5575. | 0.4 | 14 |
| 101 | Interplay between REST and nucleolin transcription factors: a key mechanism in the overexpression of genes upon increased phosphorylation. Nucleic Acids Research, 2014, 42, 2798-2798. | 6.5 | 1 |
| 102 | Identification of Factor Hâ€“like Protein 1 as the Predominant Complement Regulator in Bruchâ€™s Membrane: Implications for Age-Related Macular Degeneration. Journal of Immunology, 2014, 193, 4962-4970. | 0.4 | 102 |
| 103 | A Humanized Antibody That Regulates the Alternative Pathway Convertase: Potential for Therapy of Renal Disease Associated with Nephritic Factors. Journal of Immunology, 2014, 192, 4844-4851. | 0.4 | 29 |
| 104 | Inhibition of the Membrane Attack Complex of the Complement System Reduces Secondary Neuroaxonal Loss and Promotes Neurologic Recovery after Traumatic Brain Injury in Mice. Journal of Immunology, 2014, 192, 2339-2348. | 0.4 | 114 |
| 105 | Complement activation in multiple sclerosis plaques: an immunohistochemical analysis. Acta Neuropathologica Communications, 2014, 2, 53. | 2.4 | 124 |
| 106 | Distribution and determinants of circulating complement factor H concentration determined by a high-throughput immunonephelometric assay. Journal of Immunological Methods, 2013, 390, 63-73. | 0.6 | 33 |
| 107 | Deletion of Crry, the murine ortholog of the sporadic Alzheimer's disease risk gene CR1, impacts tau phosphorylation and brain CFH. Neuroscience Letters, 2013, 533, 96-99. | 1.0 | 15 |
| 108 | Age-related Macular Degeneration and Modification of Systemic Complement Factor H Production Through Liver Transplantation. Ophthalmology, 2013, 120, 1612-1618. | 2.5 | 39 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Common polymorphisms in the complement system and susceptiblity to bacterial meningitis. Journal of Infection, 2013, 66, 255-262. | 1.7 | 29 |
| 110 | Complement Mediated Signaling on Pulmonary CD103+ Dendritic Cells Is Critical for Their Migratory Function in Response to Influenza Infection. PLoS Pathogens, 2013, 9, e1003115. | 2.1 | 52 |
| 111 | The complement membrane attack complex triggers intracellular Ca2+ fluxes leading to NLRP3 inflammasome activation. Journal of Cell Science, 2013, 126, 2903-13. | 1.2 | 267 |
| 112 | Complement: new therapies and emergence of the complotype. ISBT Science Series, 2013, 8, 189-192. | 1.1 | 0 |
| 113 | Tissue-Specific Host Recognition by Complement Factor H Is Mediated by Differential Activities of Its Glycosaminoglycan-Binding Regions. Journal of Immunology, 2013, 190, 2049-2057. | 0.4 | 133 |
| 114 | C3 glomerulopathy: consensus report. Kidney International, 2013, 84, 1079-1089. | 2.6 | 505 |
| 115 | Dimerization of complement factor H-related proteins modulates complement activation in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 4685-4690. | 3.3 | 243 |
| 116 | Cutting Edge: The NLRP3 Inflammasome Links Complement-Mediated Inflammation and IL-1Î² Release. Journal of Immunology, 2013, 191, 1006-1010. | 0.4 | 173 |
| 117 | Affinity Purification of Human Factor H on Polypeptides Derived from Streptococcal M Protein: Enrichment of the Y402 Variant. PLoS ONE, 2013, 8, e81303. | 1.1 | 2 |
| 118 | Membrane complement regulators protect against fibrin exudation increases in a severe peritoneal inflammation model in rats. American Journal of Physiology - Renal Physiology, 2012, 302, F1245-F1251. | 1.3 | 23 |
| 119 | Systemic complement profiling in multiple sclerosis as a biomarker of disease state. Multiple Sclerosis Journal, 2012, 18, 1401-1411. | 1.4 | 67 |
| 120 | C3-dependent mechanism of microglial priming relevant to multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 965-970. | 3.3 | 124 |
| 121 | Presence and Pathogenic Relevance of Antibodies to Clustered Acetylcholine Receptor in Ocular and Generalized Myasthenia Gravis. Archives of Neurology, 2012, 69, 994-1001. | 4.9 | 111 |
| 122 | A targeted complement-dependent strategy to improve the outcome of mAb therapy, and characterization in a murine model of metastatic cancer. Blood, 2012, 119, 6043-6051. | 0.6 | 28 |
| 123 | Complement dysregulation and disease: From genes and proteins to diagnostics and drugs. Immunobiology, 2012, 217, 1034-1046. | 0.8 | 109 |
| 124 | Sensitive and specific assays for C3 nephritic factors clarify mechanisms underlying complement dysregulation. Kidney International, 2012, 82, 1084-1092. | 2.6 | 93 |
| 125 | Complement UKâ€"How and why it started. Immunobiology, 2012, 217, 125-126. | 0.8 | 1 |
| 126 | Mice expressing human CR1/CD35 have an enhanced humoral immune response to T-dependent antigens but fail to correct the effect of premature human CR2 expression. Immunobiology, 2012, 217, 147-157. | 0.8 | 8 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | Variation in complement component C1 inhibitor in age-related macular degeneration. Immunobiology, 2012, 217, 251-255. | 0.8 | 15 |
| 128 | Assembly and Regulation of the Membrane Attack Complex Based on Structures of C5b6 and sC5b9. Cell Reports, 2012, 1, 200-207. | 2.9 | 161 |
| 129 | The complotype: dictating risk for inflammation and infection. Trends in Immunology, 2012, 33, 513-521. | 2.9 | 132 |
| 130 | Complementâ€induced protection: an explanation for the limitations of cellâ€based tumour immunotherapies. Immunology and Cell Biology, 2012, 90, 869-871. | 1.0 | 3 |
| 131 | Exploiting the Nephrotoxic Effects of Venom from the Sea Anemone, Phyllodiscus semoni, to Create a Hemolytic Uremic Syndrome Model in the Rat. Marine Drugs, 2012, 10, 1582-1604. | 2.2 | 22 |
| 132 | Characterization of a large genomic deletion in four Irish families with C7 deficiency. Molecular Immunology, 2012, 50, 57-59. | 1.0 | 4 |
| 133 | Neuroblastoma: Antibody-Based Immunotherapy. Pediatric Cancer, 2012, , 105-113. | 0.0 | 0 |
| 134 | CD55 Deficiency Protects against Atherosclerosis in ApoE-Deficient Mice via C3a Modulation of Lipid Metabolism. American Journal of Pathology, 2011, 179, 1601-1607. | 1.9 | 24 |
| 135 | Lessons from functional and structural analyses of disease-associated genetic variants in the complement alternative pathway. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2011, 1812, 12-22. | 1.8 | 33 |
| 136 | Structure of Human Complement C8, a Precursor to Membrane Attack. Journal of Molecular Biology, 2011, 405, 325-330. | 2.0 | 30 |
| 137 | Complement upregulation and activation on motor neurons and neuromuscular junction in the SOD1 G93A mouse model of familial amyotrophic lateral sclerosis. Journal of Neuroimmunology, 2011, 235, 104-109. | 1.1 | 53 |
| 138 | Structures of the rat complement regulator CrrY. Acta Crystallographica Section F: Structural Biology Communications, 2011, 67, 739-743. | 0.7 | 6 |
| 139 | TLR activation enhances C5aâ€induced proâ€inflammatory responses by negatively modulating the second C5a receptor, C5L2. European Journal of Immunology, 2011, 41, 2741-2752. | 1.6 | 57 |
| 140 | Complement regulator factor H in multiple sclerosis. Journal of Cellular Biochemistry, 2011, 112, 2653-2654. | 1.2 | 9 |
| 141 | Sub-lytic C5b-9 induces functional changes in retinal pigment epithelial cells consistent with age-related macular degeneration. Eye, 2011, 25, 1074-1082. | 1.1 | 65 |
| 142 | Common polymorphisms in C3, factor B, and factor H collaborate to determine systemic complement activity and disease risk. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 8761-8766. | 3.3 | 198 |
| 143 | Structural basis for complement factor I control and its disease-associated sequence polymorphisms. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 12839-12844. | 3.3 | 118 |
| 144 | An Update on the Roles of the Complement System in Autoimmune Diseases and the Therapeutic Possibilities of Anti-Complement Agents. Current Drug Therapy, 2011, 6, 35-50. | 0.2 | 7 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | Specific collaboration between rat membrane complement regulators Crry and CD59 protects peritoneum from damage by autologous complement activation. Nephrology Dialysis Transplantation, 2011, 26, 1821-1830. | 0.4 | 22 |
| 146 | Complement component 5 contributes to poor disease outcome in humans and mice with pneumococcal meningitis. Journal of Clinical Investigation, 2011, 121, 3943-3953. | 3.9 | 98 |
| 147 | Suppression of complement activation by recombinant Crry inhibits experimental autoimmune anterior uveitis (EAAU). Molecular Immunology, 2010, 48, 231-239. | 1.0 | 15 |
| 148 | Systemic and local anti-C5 therapy reduces the disease severity in experimental autoimmune uveoretinitis. Clinical and Experimental Immunology, 2010, 159, 303-314. | 1.1 | 73 |
| 149 | Recombinant Membrane-targeted Form of CD59 Inhibits the Growth of Choroidal Neovascular Complex in Mice. Journal of Biological Chemistry, 2010, 285, 33826-33833. | 1.6 | 49 |
| 150 | Interplay between REST and nucleolin transcription factors: a key mechanism in the overexpression of genes upon increased phosphorylation. Nucleic Acids Research, 2010, 38, 2799-2812. | 6.5 | 16 |
| 151 | Hereditary Angioedema â€" Therapies Old and New. New England Journal of Medicine, 2010, 363, 581-583. | 13.9 | 40 |
| 152 | Complement Component C1q Mediates Mitochondria-Driven Oxidative Stress in Neonatal Hypoxicâ€"Ischemic Brain Injury. Journal of Neuroscience, 2010, 30, 2077-2087. | 1.7 | 84 |
| 153 | Impaired Binding of the Age-related Macular Degeneration-associated Complement Factor H 402H Allotype to Bruch's Membrane in Human Retina. Journal of Biological Chemistry, 2010, 285, 30192-30202. | 1.6 | 159 |
| 154 | Complement regulator factor H as a serum biomarker of multiple sclerosis disease state. Brain, 2010, 133, 1602-1611. | 3.7 | 78 |
| 155 | Upregulating CD59: a new strategy for protection of neurons from complement-mediated degeneration. Pharmacogenomics Journal, 2010, 10, 12-19. | 0.9 | 32 |
| 156 | Variant-specific quantification of factor H in plasma identifies null alleles associated with atypical hemolytic uremic syndrome. Kidney International, 2010, 78, 782-788. | 2.6 | 42 |
| 157 | Targeting Neural-Restrictive Silencer Factor Sensitizes Tumor Cells to Antibody-Based Cancer Immunotherapy In Vitro via Multiple Mechanisms. Journal of Immunology, 2010, 184, 6035-6042. | 0.4 | 4 |
| 158 | Membrane attack complex inhibitor CD59a protects against focal cerebral ischemia in mice. Journal of Neuroinflammation, 2010, 7, 15. | 3.1 | 49 |
| 159 | The membrane attack complex of complement drives the progression of atherosclerosis in apolipoprotein E knockout mice. Molecular Immunology, 2010, 47, 1098-1105. | 1.0 | 50 |
| 160 | Impact of compound heterozygous complement factor H mutations on development of atypical hemolytic uremic syndromeâ€"A pedigree revisited. Molecular Immunology, 2010, 47, 1585-1591. | 1.0 | 11 |
| 161 | Elevated plasma C4a levels in multiple sclerosis correlate with disease activity. Journal of Neuroimmunology, 2010, 223, 124-127. | 1.1 | 29 |
| 162 | The Alternative and Terminal Pathways of Complement Mediate Post-Traumatic Spinal Cord Inflammation and Injury. American Journal of Pathology, 2010, 177, 3061-3070. | 1.9 | 55 |

| # | Article | IF | Citations |
|---|---|---|---|
| 163 | Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation. Journal of Clinical Investigation, 2010, 120, 3702-3712. | 3.9 | 195 |
| 164 | Functional basis of protection against age-related macular degeneration conferred by a common polymorphism in complement factor B. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 4366-4371. | 3.3 | 98 |
| 165 | The disease-protective complement factor H allotypic variant Ile62 shows increased binding affinity for C3b and enhanced cofactor activity. Human Molecular Genetics, 2009, 18, 3452-3461. | 1.4 | 127 |
| 166 | Complement Abnormalities in Acquired Lipodystrophy Revisited. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 10-16. | 1.8 | 76 |
| 167 | CD59 Blockade Enhances Antigen-Specific CD4+ T Cell Responses in Humans: A New Target for Cancer Immunotherapy?. Journal of Immunology, 2009, 182, 5203-5207. | 0.4 | 46 |
| 168 | Zymosan, but Not Lipopolysaccharide, Triggers Severe and Progressive Peritoneal Injury Accompanied by Complement Activation in a Rat Peritonitis Model. Journal of Immunology, 2009, 183, 1403-1412. | 0.4 | 39 |
| 169 | A Novel Mutation in a Patient with a Deficiency of the Eighth Component of Complement Associated with Recurrent Meningococcal Meningitis. Journal of Clinical Immunology, 2009, 29, 691-695. | 2.0 | 17 |
| 170 | Complement in multiple sclerosis: its role in disease and potential as a biomarker. Clinical and Experimental Immunology, 2009, 155, 128-139. | 1.1 | 91 |
| 171 | Crry deficiency in complement sufficient mice: C3 consumption occurs without associated renal injury. Molecular Immunology, 2009, 46, 803-811. | 1.0 | 22 |
| 172 | The human complement fragment receptor, C5L2, is a recycling decoy receptor. Molecular Immunology, 2009, 46, 1149-1162. | 1.0 | 124 |
| 173 | Identification of the high affinity binding site in the Streptococcus intermedius toxin intermedilysin for its membrane receptor, the human complement regulator CD59. Molecular Immunology, 2009, 46, 1561-1567. | 1.0 | 17 |
| 174 | Deficiency of the complement regulator CD59a exacerbates Wallerian degeneration. Molecular Immunology, 2009, 46, 1892-1896. | 1.0 | 21 |
| 175 | Targeting sites of complement activation by engineering selective drug delivery. Molecular Immunology, 2009, 46, 2865. | 1.0 | 1 |
| 176 | Complement inhibition accelerates regeneration in a model of peripheral nerve injury. Molecular Immunology, 2009, 47, 302-309. | 1.0 | 26 |
| 177 | Absence of the complement regulatory molecule CD59a leads to exacerbated neuropathology after traumatic brain injury in mice. Journal of Neuroinflammation, 2009, 6, 2. | 3.1 | 72 |
| 178 | Glucocorticoids Induce Protein S-Dependent Phagocytosis of Apoptotic Neutrophils by Human Macrophages. Journal of Immunology, 2009, 183, 2167-2175. | 0.4 | 113 |
| 179 | Implication of Complement System and its Regulators in Alzheimers Disease. Current Neuropharmacology, 2009, 7, 1-8. | 1.4 | 67 |
| 180 | Myasthenia Gravis Seronegative for Acetylcholine Receptor Antibodies. Annals of the New York Academy of Sciences, 2008, 1132, 84-92. | 1.8 | 93 |

| # | Article | IF | Citations |
|---|---|---|---|
| 181 | Autoimmunizing Mechanisms in Thymoma and Thymus*. Annals of the New York Academy of Sciences, 2008, 1132, 163-173. | 1.8 | 68 |
| 182 | Thyroid follicular cell function after non-lethal complement membrane attack. Clinical and Experimental Immunology, 2008, 82, 69-74. | 1.1 | 12 |
| 183 | Antibody-mediated demyelination in experimental allergic encephalomyelitis is independent of complement membrane attack complex formation. Clinical and Experimental Immunology, 2008, 83, 245-250. | 1.1 | 80 |
| 184 | The complement-inhibiting protein, Protectin (CD59 antigen), is present and functionally active on glomerular epithelial cells. Clinical and Experimental Immunology, 2008, 83, 251-256. | 1.1 | 39 |
| 185 | Functionally active complement proteins C6 and C7 detected in C6- and C7-deficient individuals. Clinical and Experimental Immunology, 2008, 83, 430-437. | 1.1 | 58 |
| 186 | A component of the medicinal herb ephedra blocks activation in the classical and alternative pathways of complement. Clinical and Experimental Immunology, 2008, 102, 582-588. | 1.1 | 27 |
| 187 | The role of complement and complement regulators in mediating motor nerve terminal injury in murine models of Guillainâ€“BarrÃ© syndrome. Journal of Neuroimmunology, 2008, 201-202, 172-182. | 1.1 | 59 |
| 188 | Bacterial expression and membrane targeting of the rat complement regulator Crry: A new model anticomplement therapeutic. Protein Science, 2008, 11, 2512-2521. | 3.1 | 14 |
| 189 | Prevention of experimental autoimmune myasthenia gravis by rat Crry-Ig: A model agent for long-term complement inhibition in vivo. Molecular Immunology, 2008, 45, 395-405. | 1.0 | 27 |
| 190 | Complement Factor H Binds to Denatured Rather than to Native Pentameric C-reactive Protein. Journal of Biological Chemistry, 2008, 283, 30451-30460. | 1.6 | 82 |
| 191 | Modulation of CD59 Expression by Restrictive Silencer Factorâ€“Derived Peptides in Cancer Immunotherapy for Neuroblastoma. Cancer Research, 2008, 68, 5979-5987. | 0.4 | 27 |
| 192 | Measurement of Factor H Variants in Plasma Using Variant-Specific Monoclonal Antibodies: Application to Assessing Risk of Age-Related Macular Degeneration. , 2008, 49, 1983. | | 80 |
| 193 | IgG1 antibodies to acetylcholine receptors in â€˜seronegativeâ€™ myasthenia gravisâ€. Brain, 2008, 131, 1940-1952. | 3.7 | 438 |
| 194 | Circulating neutrophils maintain physiological blood pressure by suppressing bacteria and IFNÎ³-dependent iNOS expression in the vasculature of healthy mice. Blood, 2008, 111, 5187-5194. | 0.6 | 43 |
| 195 | Complement, roles in renal disease and modulation for therapy. Clinical Nephrology, 2008, 70, 357-376. | 0.4 | 10 |
| 196 | In Vivo Characterization and Therapeutic Efficacy of a C5-specific Inhibitor from the Soft Tick Ornithodoros moubata. Journal of Biological Chemistry, 2007, 282, 8292-8299. | 1.6 | 75 |
| 197 | Decay-Accelerating Factor Must Bind Both Components of the Complement Alternative Pathway C3 Convertase to Mediate Efficient Decay. Journal of Immunology, 2007, 178, 352-359. | 0.4 | 40 |
| 198 | CD59, a Complement Regulatory Protein, Controls Choroidal Neovascularization in a Mouse Model of Wet-Type Age-Related Macular Degeneration. Journal of Immunology, 2007, 178, 1783-1790. | 0.4 | 94 |

| # | Article | IF | Citations |
|---|---|---|---|
| 199 | The Membrane Attack Complex of the Complement System Is Essential for Rapid Wallerian Degeneration. Journal of Neuroscience, 2007, 27, 7663-7672. | 1.7 | 68 |
| 200 | Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 240-245. | 3.3 | 429 |
| 201 | Alternative roles for CD59. Molecular Immunology, 2007, 44, 73-81. | 1.0 | 132 |
| 202 | CD55 in rat male reproductive tissue: Differential expression in testis and expression of a unique truncated isoform on spermatozoa. Molecular Immunology, 2007, 44, 1613-1622. | 1.0 | 5 |
| 203 | Prevalence of mutations leading to complete C6 deficiency (C6Q0) in the Western Cape, South Africa and detection of novel mutations leading to C6Q0 in an Irish family. Molecular Immunology, 2007, 44, 2756-2760. | 1.0 | 17 |
| 204 | CD59a deficient mice display reduced B cell activity and antibody production in response to T-dependent antigens. Molecular Immunology, 2007, 44, 2978-2987. | 1.0 | 8 |
| 205 | A Protein Toxin from the Sea Anemone Phyllodiscus semoni Targets the Kidney and Causes a Severe Renal Injury with Predominant Glomerular Endothelial Damage. American Journal of Pathology, 2007, 171, 402-414. | 1.9 | 37 |
| 206 | Myasthenia Gravis Thymus. American Journal of Pathology, 2007, 171, 893-905. | 1.9 | 113 |
| 207 | CD59a deficiency exacerbates influenza-induced lung inflammation through complement-dependent and -independent mechanisms. European Journal of Immunology, 2007, 37, 1266-1274. | 1.6 | 31 |
| 208 | High-resolution structures of bacterially expressed soluble human CD59. Acta Crystallographica Section F: Structural Biology Communications, 2007, 63, 648-652. | 0.7 | 25 |
| 209 | CD59 or C3 are not requred for angiotensin II-dependent hypertension or hypertrophy in mice. Immunology, 2007, 121, 518-528. | 2.0 | 11 |
| 210 | Immunization with autologous CD46 generates a strong autoantibody response in rats that targets spermatozoa. Journal of Reproductive Immunology, 2007, 73, 135-147. | 0.8 | 10 |
| 211 | Complement and complement regulators in the male reproductive system. Molecular Immunology, 2006, 43, 57-67. | 1.0 | 53 |
| 212 | Letter in response to A. Agrawal: â€˜CRP after 2004â€™. Molecular Immunology, 2006, 43, 292-293. | 1.0 | 2 |
| 213 | Complement regulator loss on apoptotic neuronal cells causes increased complement activation and promotes both phagocytosis and cell lysis. Molecular Immunology, 2006, 43, 1953-1964. | 1.0 | 54 |
| 214 | Holding T cells in check â€“ a new role for complement regulators?. Trends in Immunology, 2006, 27, 102-108. | 2.9 | 100 |
| 215 | The membrane attack pathway of complement drives pathology in passively induced experimental autoimmune myasthenia gravis in mice. Clinical and Experimental Immunology, 2006, 146, 294-302. | 1.1 | 82 |
| 216 | Complement membrane attack is required for endplate damage and clinical disease in passive experimental myasthenia gravis in Lewis rats. Clinical and Experimental Immunology, 2006, 146, 278-286. | 1.1 | 54 |

| # | Article | IF | Citations |
|---|---|---|---|
| 217 | A quantitative method for comparison of expression of alternatively spliced genes using different primer pairs. Journal of Proteomics, 2006, 66, 23-31. | 2.4 | 4 |
| 218 | Complement regulator CD59 deficiency fails to augment susceptibility to actively induced experimental autoimmune myasthenia gravis. Journal of Neuroimmunology, 2006, 181, 29-33. | 1.1 | 14 |
| 219 | Spermatogenic cells distal to the bloodâ€“testis barrier in rats lack C3 convertase regulators and may be at risk of complement-mediated injury. Journal of Reproductive Immunology, 2006, 69, 23-34. | 0.8 | 13 |
| 220 | p53 Regulates Cellular Resistance to Complement Lysis through Enhanced Expression of CD59. Cancer Research, 2006, 66, 2451-2458. | 0.4 | 29 |
| 221 | Expression of Glycosylphosphatidylinositol-Anchored CD59 on Target Cells Enhances Human NK Cell-Mediated Cytotoxicity. Journal of Immunology, 2006, 176, 2915-2923. | 0.4 | 24 |
| 222 | Complement: central to innate immunity and bridging to adaptive responses. Immunology Letters, 2005, 97, 171-179. | 1.1 | 178 |
| 223 | ''Homologous restriction'' in complement lysis: roles of membrane complement regulators. Xenotransplantation, 2005, 12, 258-265. | 1.6 | 74 |
| 224 | Glycation of CD59 impairs complement regulation on erythrocytes from diabetic subjects. Immunology, 2005, 114, 280-286. | 2.0 | 27 |
| 225 | Loxosceles Sphingomyelinase Induces Complement-Dependent Dermonecrosis, Neutrophil Infiltration, and Endogenous Gelatinase Expression. Journal of Investigative Dermatology, 2005, 124, 725-731. | 0.3 | 72 |
| 226 | The Role of Complement in EAE. , 2005, , 245-267. | | 2 |
| 227 | Inhibition of Coxsackie B Virus Infection by Soluble Forms of Its Receptors: Binding Affinities, Altered Particle Formation, and Competition with Cellular Receptors. Journal of Virology, 2005, 79, 12016-12024. | 1.5 | 61 |
| 228 | CD46 Plays a Key Role in Tailoring Innate Immune Recognition of Apoptotic and Necrotic Cells. Journal of Biological Chemistry, 2005, 280, 36342-36354. | 1.6 | 126 |
| 229 | B Cells from Mice Prematurely Expressing Human Complement Receptor Type 2 Are Unresponsive to T-Dependent Antigens. Journal of Immunology, 2005, 174, 6974-6982. | 0.4 | 16 |
| 230 | Cutting Edge: Murine CD59a Modulates Antiviral CD4+ T Cell Activity in a Complement-Independent Manner. Journal of Immunology, 2005, 175, 7098-7102. | 0.4 | 67 |
| 231 | Decay-Accelerating Factor (CD55) Is Expressed by Neurons in Response to Chronic but Not Acute Autoimmune Central Nervous System Inflammation Associated with Complement Activation. Journal of Immunology, 2005, 174, 2353-2365. | 0.4 | 61 |
| 232 | Molecular Dissection of Interactions between Components of the Alternative Pathway of Complement and Decay Accelerating Factor (CD55). Journal of Biological Chemistry, 2005, 280, 2569-2578. | 1.6 | 78 |
| 233 | Expression of CD46 in Developing Rat Spermatozoa: Ultrastructural Localization and Utility as a Marker of the Various Stages of the Seminiferous Tubuli1. Biology of Reproduction, 2005, 72, 908-915. | 1.2 | 15 |
| 234 | Insights into the Human CD59 Complement Binding Interface Toward Engineering New Therapeutics. Journal of Biological Chemistry, 2005, 280, 34073-34079. | 1.6 | 31 |

| # | Article | IF | Citations |
|---|---|---|---|
| 235 | Structureâ€“Function Relationships in CD59. , 2005, , 251-263. | | 0 |
| 236 | Structureâ€“Function Relationships in CD59. , 2005, , 251-264. | | 2 |
| 237 | The Possibilities and Pitfalls for Anti-Complement Therapies in Inflammatory Diseases. Inflammation and Allergy: Drug Targets, 2004, 3, 87-96. | 3.1 | 30 |
| 238 | Rat Membrane Cofactor Protein (MCP; CD46) Is Expressed Only in the Acrosome of Developing and Mature Spermatozoa and Mediates Binding to Immobilized Activated C31. Biology of Reproduction, 2004, 71, 1374-1383. | 1.2 | 42 |
| 239 | Human Diffusely Adhering Escherichia coli Expressing Afa/Dr Adhesins That Use Human CD55 (Decay-Accelerating Factor) as a Receptor Does Not Bind the Rodent and Pig Analogues of CD55. Infection and Immunity, 2004, 72, 4859-4863. | 1.0 | 16 |
| 240 | Complement regulation at the molecular level: The structure of decay-accelerating factor. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 1279-1284. | 3.3 | 112 |
| 241 | CD59a Is the Primary Regulator of Membrane Attack Complex Assembly in the Mouse. Journal of Immunology, 2004, 173, 3684-3692. | 0.4 | 70 |
| 242 | Respective Roles of Decay-Accelerating Factor and CD59 in Circumventing Glomerular Injury in Acute Nephrotoxic Serum Nephritis. Journal of Immunology, 2004, 172, 2636-2642. | 0.4 | 41 |
| 243 | The Many Faces of the Membrane Regulators of Complement. , 2004, , 129-166. | | 1 |
| 244 | Blockade of the C5a receptor fails to protect against experimental autoimmune encephalomyelitis in rats. Clinical and Experimental Immunology, 2004, 138, 430-438. | 1.1 | 32 |
| 245 | Deficiency of the complement regulator CD59a enhances disease severity, demyelination and axonal injury in murine acute experimental allergic encephalomyelitis. Laboratory Investigation, 2004, 84, 21-28. | 1.7 | 82 |
| 246 | Biological activity, membrane-targeting modification, and crystallization of soluble human decay accelerating factor expressed inE. coli. Protein Science, 2004, 13, 2406-2415. | 3.1 | 40 |
| 247 | Deletion of the gene encoding CD59a in mice increases disease severity in a murine model of rheumatoid arthritis. Arthritis and Rheumatism, 2004, 50, 3035-3044. | 6.7 | 53 |
| 248 | Analysis of the level of mRNA expression of the membrane regulators of complement, CD59, CD55 and CD46, in breast cancer. International Journal of Cancer, 2004, 108, 930-936. | 2.3 | 42 |
| 249 | Monoglucosylated glycans in the secreted human complement component C3: implications for protein biosynthesis and structure. FEBS Letters, 2004, 566, 270-274. | 1.3 | 47 |
| 250 | CD59a Deficiency Exacerbates Ischemia-Reperfusion Injury in Mice. American Journal of Pathology, 2004, 165, 825-832. | 1.9 | 37 |
| 251 | Molecular cloning, expression, function and immunoreactivities of members of a gene family of sphingomyelinases from Loxosceles venom glands1. Molecular Immunology, 2004, 41, 831-840. | 1.0 | 68 |
| 252 | Deficiency of the complement regulator CD59a enhances disease severity, demyelination and axonal injury in murine acute experimental allergic encephalomyelitis. Laboratory Investigation, 2004, 84, 21-28. | 1.7 | 11 |

| # | Article | IF | Citations |
|---|---|---|---|
| 253 | Antigen-presenting cell exosomes are protected from complement-mediated lysis by expression of CD55 and CD59. European Journal of Immunology, 2003, 33, 522-531. | 1.6 | 277 |
| 254 | An abnormal but functionally active complement component C9 protein found in an Irish family with subtotal C9 deficiency. Immunology, 2003, 108, 384-390. | 2.0 | 8 |
| 255 | Characterization of the mouse analogues of CD59 using novel monoclonal antibodies: tissue distribution and functional comparison. Immunology, 2003, 109, 117-126. | 2.0 | 59 |
| 256 | Complement therapeutics; history and current progress. Molecular Immunology, 2003, 40, 159-170. | 1.0 | 143 |
| 257 | CD59a Deficiency Exacerbates Accelerated Nephrotoxic Nephritis in Mice. Journal of the American Society of Nephrology: JASN, 2003, 14, 2271-2279. | 3.0 | 32 |
| 258 | Complement Regulation by Kaposi's Sarcoma-Associated Herpesvirus ORF4 Protein. Journal of Virology, 2003, 77, 592-599. | 1.5 | 91 |
| 259 | Generation of Anti-complement â€œProdrugsâ€• Journal of Biological Chemistry, 2003, 278, 36068-36076. | 1.6 | 22 |
| 260 | Soluble Forms of Toll-Like Receptor (TLR)2 Capable of Modulating TLR2 Signaling Are Present in Human Plasma and Breast Milk. Journal of Immunology, 2003, 171, 6680-6689. | 0.4 | 301 |
| 261 | Generation of a Recombinant, Membrane-targeted Form of the Complement Regulator CD59. Journal of Biological Chemistry, 2003, 278, 48921-48927. | 1.6 | 61 |
| 262 | Complement C3a receptors in the pituitary gland: a novel pathway by which an innate immune molecule releases hormones involved in the control of inflammation. FASEB Journal, 2003, 17, 2266-2268. | 0.2 | 59 |
| 263 | Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood, 2003, 101, 1045-1052. | 0.6 | 353 |
| 264 | CD59 Deficiency Exacerbates Accelerated Nephrotoxic Nephritis. Clinical Science, 2003, 104, 49P-49P. | 0.0 | 0 |
| 265 | Beyond lysis: how complement influences cell fate. Clinical Science, 2003, 104, 455-466. | 1.8 | 166 |
| 266 | The Membrane Attack Complex of Complement Causes Severe Demyelination Associated with Acute Axonal Injury. Journal of Immunology, 2002, 168, 458-465. | 0.4 | 183 |
| 267 | Expression of Human Complement Receptor Type 2 (CD21) in Mice During Early B Cell Development Results in a Reduction in Mature B Cells and Hypogammaglobulinemia. Journal of Immunology, 2002, 169, 3526-3535. | 0.4 | 28 |
| 268 | Human C1qRp Is Identical with CD93 and the mNI-11 Antigen But Does Not Bind C1q. Journal of Immunology, 2002, 168, 5222-5232. | 0.4 | 110 |
| 269 | Complement activation in postpartum thyroiditis. QJM - Monthly Journal of the Association of Physicians, 2002, 95, 173-179. | 0.2 | 9 |
| 270 | Tailoring anti-complement therapeutics. Biochemical Society Transactions, 2002, 30, 1019-1026. | 1.6 | 28 |

| # | Article | IF | Citations |
|---|---|---|---|
| 271 | Glycosylation and the Complement System. Chemical Reviews, 2002, 102, 305-320. | 23.0 | 155 |
| 272 | GPI-anchored GFP signals Ca2+ but is homogeneously distributed on the cell surface. Biochemical and Biophysical Research Communications, 2002, 293, 714-721. | 1.0 | 24 |
| 273 | Efficient generation of monoclonal antibodies for specific protein domains using recombinant immunoglobulin fusion proteins: pitfalls and solutions. Journal of Immunological Methods, 2002, 268, 245-258. | 0.6 | 24 |
| 274 | Rat T cells express neither CD55 nor CD59 and are dependent on Crry for protection from homologous complement. European Journal of Immunology, 2002, 32, 502-509. | 1.6 | 4 |
| 275 | Decay-accelerating factor expression in the rat kidney is restricted to the apical surface of podocytes. Kidney International, 2002, 62, 2010-2021. | 2.6 | 26 |
| 276 | Coupling complement regulators to immunoglobulin domains generates effective anti-complement reagents with extended half-lifein vivo. Clinical and Experimental Immunology, 2002, 129, 198-207. | 1.1 | 46 |
| 277 | Roles of the Complement System in Human Neurodegenerative Disorders. Molecular Neurobiology, 2002, 25, 001-018. | 1.9 | 69 |
| 278 | Coxsackie B viruses that use human DAF as a receptor infect pig cells via pig CAR and do not use pig DAF. Journal of General Virology, 2002, 83, 45-52. | 1.3 | 21 |
| 279 | Human Factor H-related Protein 5 (FHR-5). Journal of Biological Chemistry, 2001, 276, 6747-6754. | 1.6 | 67 |
| 280 | Targeted deletion of the CD59 gene causes spontaneous intravascular hemolysis and hemoglobinuria. Blood, 2001, 98, 442-449. | 0.6 | 139 |
| 281 | Outcome of bedside percutaneous tracheostomy with bronchoscopic guidance. Intensive Care Medicine, 2001, 27, 1553-1553. | 3.9 | 1 |
| 282 | Glomerular complement regulation is overwhelmed in passive Heymann nephritis. Kidney International, 2001, 60, 900-909. | 2.6 | 27 |
| 283 | Characterization of glycosylphosphatidylinositol-anchored decay accelerating factor (GPI-DAF) and transmembrane DAF gene expression in wild-type and GPI-DAF gene knockout mice using polyclonal and monoclonal antibodies with dual or single specificity. Immunology, 2001, 104, 207-214. | 2.0 | 47 |
| 284 | The lipopolysaccharide co-receptor CD14 is present and functional in seminal plasma and expressed on spermatozoa. Immunology, 2001, 104, 317-323. | 2.0 | 24 |
| 285 | Immunopathology of secondary-progressive multiple sclerosis. Annals of Neurology, 2001, 50, 646-657. | 2.8 | 371 |
| 286 | Membrane complement regulators protect against the development of type II collagen-induced arthritis in rats. Arthritis and Rheumatism, 2001, 44, 2425-2434. | 6.7 | 36 |
| 287 | Complement in Inflammation. , 2001, , 131-145. | | 4 |
| 288 | ROLE AND REGULATION OF PIG CD59 AND MEMBRANE COFACTOR PROTEIN/CD46 EXPRESSED ON PIG AORTIC ENDOTHELIAL CELLS1. Transplantation, 2000, 70, 667-673. | 0.5 | 19 |

| # | Article | IF | Citations |
|---|---|---|---|
| 289 | Therapeutic efficacy of a novel membrane-targeted complement regulator in antigen-induced arthritis in the rat. Arthritis and Rheumatism, 2000, 43, 2590-2597. | 6.7 | 61 |
| 290 | CD59 protects rat kidney from complement mediated injury in collaboration with Crry. Kidney International, 2000, 58, 1569-1579. | 2.6 | 21 |
| 291 | Comparison of the suppressive effects of soluble CR1 and C5a receptor antagonist in acute arthritis induced in rats by blocking of CD59. Clinical and Experimental Immunology, 2000, 119, 368-375. | 1.1 | 31 |
| 292 | Soluble complement receptor one (sCR1) inhibits the development and progression of rat collagen-induced arthritis. Clinical and Experimental Immunology, 2000, 119, 210-216. | 1.1 | 55 |
| 293 | Cytokine-mediated up-regulation of CD55 and CD59 protects human hepatoma cells from complement attack. Clinical and Experimental Immunology, 2000, 121, 234-241. | 1.1 | 64 |
| 294 | Human and rodent decay-accelerating factors (CD55) are not species restricted in their complement-inhibiting activities. Immunology, 2000, 100, 462-470. | 2.0 | 71 |
| 295 | Production and functional characterization of a soluble recombinant form ofmouse CD59. Immunology, 2000, 99, 326-332. | 2.0 | 5 |
| 296 | Production and functional analysis of rat CD59 and chimeric CD59-Crry as active soluble proteins inPichia pastoris. Immunology, 2000, 99, 46-53. | 2.0 | 16 |
| 297 | Complement components of the innate immune system in health and disease in the CNS. Immunopharmacology, 2000, 49, 171-186. | 2.0 | 324 |
| 298 | Complement mediated cell death is associated with DNA fragmentation. Cell Death and Differentiation, 2000, 7, 48-58. | 5.0 | 50 |
| 299 | Membrane attack complex formation on yeast as trigger of selective release of terminal complement proteins from human polymorphonuclear leukocytes. FEMS Immunology and Medical Microbiology, 2000, 28, 15-23. | 2.7 | 13 |
| 300 | Immunology of reproduction: Protecting the placenta. Current Biology, 2000, 10, R381-R383. | 1.8 | 34 |
| 301 | Loxosceles intermedia spider envenomation induces activation of an endogenous metalloproteinase, resulting in cleavage of glycophorins from the erythrocyte surface and facilitating complement-mediated lysis. Blood, 2000, 95, 683-691. | 0.6 | 94 |
| 302 | Echoviruses and Coxsackie B Viruses That Use Human Decayâ€Accelerating Factor (DAF) as a Receptor Do Not Bind the Rodent Analogues of DAF. Journal of Infectious Diseases, 2000, 181, 340-343. | 1.9 | 37 |
| 303 | The Complement System: An Overview. , 2000, 150, 1-13. | | 65 |
| 304 | Immunoaffinity Methods for Purification of Complement Components and Regulators. , 2000, 150, 53-60. | | 1 |
| 305 | Pigs Express Multiple Forms of Decay-Accelerating Factor (CD55), All of Which Contain Only Three Short Consensus Repeats. Journal of Immunology, 2000, 165, 2563-2573. | 0.4 | 42 |
| 306 | Genomic structure and chromosome location of the gene encoding mouse CD59. Cytogenetic and Genome Research, 2000, 89, 264-267. | 0.6 | 8 |

| # | Article | IF | Citations |
|---|---|---|---|
| 307 | Innate Recognition of Bacteria in Human Milk Is Mediated by a Milk-Derived Highly Expressed Pattern Recognition Receptor, Soluble Cd14. Journal of Experimental Medicine, 2000, 191, 1807-1812. | 4.2 | 211 |
| 308 | Spontaneous Classical Pathway Activation and Deficiency of Membrane Regulators Render Human Neurons Susceptible to Complement Lysis. American Journal of Pathology, 2000, 157, 905-918. | 1.9 | 150 |
| 309 | Measurement of Complement Hemolytic Activity, Generation of Complement-Depleted Sera, and Production of Hemolytic Intermediates. , 2000, 150, 61-71. | | 40 |
| 310 | Identification of Mutations in Rat CD59 That Increase the Complement Regulatory Activityâ€. Biochemistry, 2000, 39, 5831-5837. | 1.2 | 3 |
| 311 | THE PIG ANALOGUE OF CD59 PROTECTS TRANSGENIC MOUSE HEARTS FROM INJURY BY HUMAN COMPLEMENT1. Transplantation, 2000, 70, 963-968. | 0.5 | 28 |
| 312 | CD59. , 2000, , 219-221. | | 0 |
| 313 | Hypoxia-induced expression of complement receptor type 1 (CR1, CD35) in human vascular endothelial cells. American Journal of Physiology - Cell Physiology, 1999, 276, C450-C458. | 2.1 | 45 |
| 314 | Induction of Decay-Accelerating Factor by Cytokines or the Membrane-Attack Complex Protects Vascular Endothelial Cells Against Complement Deposition. Blood, 1999, 94, 1673-1682. | 0.6 | 107 |
| 315 | Identification of the Individual Residues That Determine Human CD59 Species Selective Activity. Journal of Biological Chemistry, 1999, 274, 10969-10974. | 1.6 | 22 |
| 316 | Protection of human breast cancer cells from complement-mediated lysis by expression of heterologous CD59. Clinical and Experimental Immunology, 1999, 115, 13-18. | 1.1 | 33 |
| 317 | Properdin deficiency and meningococcal disease-identifying those most at risk. Clinical and Experimental Immunology, 1999, 118, 189-191. | 1.1 | 39 |
| 318 | Role of complement regulatory membrane proteins in ischaemia-reperfusion injury of rat gastric mucosa. Journal of Gastroenterology and Hepatology (Australia), 1999, 14, 967-972. | 1.4 | 10 |
| 319 | Epitope mapping of 10 monoclonal antibodies against the pig analogue of human membrane cofactor protein (MCP). Immunology, 1999, 96, 663-670. | 2.0 | 15 |
| 320 | Tissue distribution of the rat analogue of decayâ€accelerating factor. Immunology, 1999, 97, 374-384. | 2.0 | 36 |
| 321 | Distribution of membrane cofactor protein (MCP/CD46) on pig tissues. Relevance to xenotransplantation. Immunology, 1999, 98, 144-151. | 2.0 | 22 |
| 322 | Molecular cloning, expression and characterization of the rat analogue of human membrane cofactor protein (MCP/CD46). Immunology, 1999, 98, 137-143. | 2.0 | 45 |
| 323 | Efficient generation of monoclonal antibodies against surface-expressed proteins by hyperexpression in rodent cells. Journal of Immunological Methods, 1999, 224, 51-60. | 0.6 | 32 |
| 324 | Miller Fisher anti-GQ1b antibodies: ?-Latrotoxin-like effects on motor end plates. Annals of Neurology, 1999, 45, 189-199. | 2.8 | 203 |

| # | Article | IF | Citations |
|---|---|---|---|
| 325 | Complement activation and inhibition in experimental models of arthritis. Molecular Immunology, 1999, 36, 905-914. | 1.0 | 83 |
| 326 | Increased Complement Biosynthesis By Microglia and Complement Activation on Neurons in Huntington's Disease. Experimental Neurology, 1999, 159, 362-376. | 2.0 | 280 |
| 327 | Molecular and functional analysis of mouse decay accelerating factor (CD55). Biochemical Journal, 1999, 341, 821-829. | 1.7 | 50 |
| 328 | Molecular and functional analysis of mouse decay accelerating factor (CD55). Biochemical Journal, 1999, 341, 821. | 1.7 | 22 |
| 329 | Induction of Decay-Accelerating Factor by Cytokines or the Membrane-Attack Complex Protects Vascular Endothelial Cells Against Complement Deposition. Blood, 1999, 94, 1673-1682. | 0.6 | 84 |
| 330 | Regulation of the Complement Membrane Attack Pathway. Critical Reviews in Immunology, 1999, 19, 26. | 1.0 | 186 |
| 331 | Molecular and functional analysis of mouse decay accelerating factor (CD55). Biochemical Journal, 1999, 341 ( Pt 3), 821-9. | 1.7 | 19 |
| 332 | Regulation of the complement membrane attack pathway. Critical Reviews in Immunology, 1999, 19, 173-98. | 1.0 | 77 |
| 333 | Induction of decay-accelerating factor by cytokines or the membrane-attack complex protects vascular endothelial cells against complement deposition. Blood, 1999, 94, 1673-82. | 0.6 | 36 |
| 334 | Differential expression of individual complement regulators in the brain and choroid plexus. Laboratory Investigation, 1999, 79, 1247-59. | 1.7 | 38 |
| 335 | Development of adenovirus vectors encoding rat complement regulators for use in therapy in rodent models of inflammatory diseases. Journal of Immunology, 1999, 163, 6834-40. | 0.4 | 10 |
| 336 | Complement activation and CD59 expression in the motor facial nucleus following intracranial transection of the facial nerve in the adult rat. Journal of Neuroimmunology, 1998, 91, 180-189. | 1.1 | 19 |
| 337 | Multiple sclerosis: In situ evidence for antibody- and complement-mediated demyelination. Annals of Neurology, 1998, 43, 465-471. | 2.8 | 390 |
| 338 | Vaccination against meningococcus in complement-deficient individuals. Clinical and Experimental Immunology, 1998, 114, 327-329. | 1.1 | 22 |
| 339 | The expression of complement regulatory proteins by adult human oligodendrocytes. Journal of Neuroimmunology, 1998, 84, 69-75. | 1.1 | 62 |
| 340 | Sphingomyelinases in the Venom of the SpiderLoxosceles intermediaAre Responsible for both Dermonecrosis and Complement-Dependent Hemolysis. Biochemical and Biophysical Research Communications, 1998, 251, 366-373. | 1.0 | 154 |
| 341 | Antibodyâ€Independent Activation of the Classical Complement Pathway by Cytomegalovirusâ€Infected Fibroblasts. Journal of Infectious Diseases, 1998, 178, 1597-1603. | 1.9 | 28 |
| 342 | Therapeutic uses of recombinant complement receptors. Biochemical Society Transactions, 1998, 26, 49-54. | 1.6 | 16 |

| # | Article | IF | Citations |
|---|---|---|---|
| 343 | Characterization in vitro and in vivo of the pig analogue of human CD59 using new monoclonal antibodies. Immunology, 1998, 95, 450-459. | 2.0 | 14 |
| 344 | The Glycosylation of the Complement Regulatory Protein, Human Erythrocyte CD59. Advances in Experimental Medicine and Biology, 1998, 435, 153-162. | 0.8 | 11 |
| 345 | CD59 protects glomerular endothelial cells from immune-mediated thrombotic microangiopathy in rats.. Journal of the American Society of Nephrology: JASN, 1998, 9, 590-597. | 3.0 | 71 |
| 346 | A bispecific monoclonal antibody directed against both the membrane-bound complement regulator CD55 and the renal tumor-associated antigen G250 enhances C3 deposition and tumor cell lysis by complement. Journal of Immunology, 1998, 160, 3437-43. | 0.4 | 38 |
| 347 | The receptor for complement anaphylatoxin C3a is expressed by myeloid cells and nonmyeloid cells in inflamed human central nervous system: analysis in multiple sclerosis and bacterial meningitis. Journal of Immunology, 1998, 160, 3543-54. | 0.4 | 139 |
| 348 | Molecular cloning and functional characterization of the pig analogue of CD59: relevance to xenotransplantation. Journal of Immunology, 1998, 160, 3924-32. | 0.4 | 47 |
| 349 | Molecular cloning and functional characterization of the rat analogue of human decay-accelerating factor (CD55). Journal of Immunology, 1998, 161, 5695-703. | 0.4 | 31 |
| 350 | The Glycosylation of the Complement Regulatory Protein, Human Erythrocyte CD59. Journal of Biological Chemistry, 1997, 272, 7229-7244. | 1.6 | 154 |
| 351 | Mutational Analysis of the Active Site and Antibody Epitopes of the Complement-inhibitory Glycoprotein, CD59. Journal of Experimental Medicine, 1997, 185, 507-516. | 4.2 | 94 |
| 352 | Roles for glycosylation in the anti-inflammatory molecule CD59. Biochemical Society Transactions, 1997, 25, 1177-1184. | 1.6 | 6 |
| 353 | Extrahepatic complement biosynthesis: where, when and why?. Clinical and Experimental Immunology, 1997, 107, 1-7. | 1.1 | 331 |
| 354 | Mapping the Regions of the Complement Inhibitor CD59 Responsible for Its Species Selective Activity. Biochemistry, 1997, 36, 9423-9428. | 1.2 | 27 |
| 355 | Perforin is activated by a proteolytic cleavage during biosynthesis which reveals a phospholipid-binding C2 domain. EMBO Journal, 1997, 16, 7287-7296. | 3.5 | 167 |
| 356 | Mechanisms of complement resistance induced by nonâ€lethal complement attack and by growth arrest. Immunology, 1997, 90, 647-653. | 2.0 | 12 |
| 357 | Tumour cell killing using chemically engineered antibody constructs specific for tumour cells and the complement inhibitor CD59. Clinical and Experimental Immunology, 1997, 107, 364-371. | 1.1 | 27 |
| 358 | Local therapy with soluble complement receptor 1 (sCR1) suppresses inflammation in rat mono-articular arthritis. Clinical and Experimental Immunology, 1997, 110, 45-52. | 1.1 | 36 |
| 359 | The role of complement in disorders of the nervous system. Immunopharmacology, 1997, 38, 43-50. | 2.0 | 77 |
| 360 | Binding of human and rat CD59 to the terminal complement complexes. Immunology, 1997, 90, 121-128. | 2.0 | 12 |

| # | Article | IF | Citations |
|---|---|---|---|
| 361 | Expression of rat CD59: functional analysis confirms lack of species selectivity and reveals that glycosylation is not required for function. Immunology, 1997, 90, 640-646. | 2.0 | 28 |
| 362 | The effects of functional suppression of a membrane-bound complement regulatory protein, CD59, in the synovial tissue in rats. Arthritis and Rheumatism, 1997, 40, 527-533. | 6.7 | 35 |
| 363 | Local therapy with soluble complement receptor 1 (sCR1) suppresses inflammation in rat mono-articular arthritis. Clinical and Experimental Immunology, 1997, 110, 45-52. | 1.1 | 23 |
| 364 | Development of a model for cytomegalovirus infection of oligodendrocytes.. Journal of General Virology, 1997, 78, 3349-3356. | 1.3 | 32 |
| 365 | The Administration of Complement Component C9 Enhances the Survival of Neonatal Rats with Escherichia coli Sepsis1. Pediatric Research, 1997, 42, 128-136. | 1.1 | 28 |
| 366 | Expression of the receptor for complement C5a (CD88) is up-regulated on reactive astrocytes, microglia, and endothelial cells in the inflamed human central nervous system. American Journal of Pathology, 1997, 150, 31-41. | 1.9 | 179 |
| 367 | Molecular cloning, chromosomal localization, expression, and functional characterization of the mouse analogue of human CD59. Journal of Immunology, 1997, 158, 1692-702. | 0.4 | 63 |
| 368 | Purification and characterization of the pig analogue of human membrane cofactor protein (CD46/MCP). Journal of Immunology, 1997, 158, 1703-9. | 0.4 | 42 |
| 369 | Role of complement in inflammation and injury in the nervous system. Experimental and Clinical Immunogenetics, 1997, 14, 19-23. | 1.4 | 12 |
| 370 | Complement activation on human neuroblastoma cell lines in vitro: route of activation and expression of functional complement regulatory proteins. Journal of Neuroimmunology, 1996, 66, 29-40. | 1.1 | 78 |
| 371 | CD59 homologue regulates complement-dependent cytolysis of rat Schwann cells. Journal of Neuroimmunology, 1996, 69, 63-71. | 1.1 | 22 |
| 372 | Target-sensitive immunoerythrocytes: interaction of biotinylated red blood cells with immobilized avidin induces their lysis by complement. Biochimica Et Biophysica Acta - Biomembranes, 1996, 1279, 137-143. | 1.4 | 17 |
| 373 | Complement expression on astrocytes and astrocytoma cell lines: failure of complement regulation at the C3 level correlates with very low CD55 expression. Journal of Neuroimmunology, 1996, 71, 97-106. | 1.1 | 21 |
| 374 | Soluble complement receptor 1 (sCR1) protects against experimental autoimmune myasthenia gravis. Journal of Neuroimmunology, 1996, 71, 173-177. | 1.1 | 106 |
| 375 | Role of Complement in the Aetiology of PickÊ¼s Disease?. Journal of Neuropathology and Experimental Neurology, 1996, 55, 578-593. | 0.9 | 58 |
| 376 | Chapter 10 Activation and control of the complement system. Principles of Medical Biology, 1996, , 171-196. | 0.1 | 0 |
| 377 | Intervention in the complement system: A therapeutic strategy in inflammation. Biochemical Society Transactions, 1996, 24, 224-229. | 1.6 | 14 |
| 378 | Effects of inhibition of complement activation using recombinant soluble complement receptor 1 on neutrophil CD11b/CD18 and l-selectin expression and release of interleukin-8 and elastase in simulated cardiopulmonary bypass. Journal of Thoracic and Cardiovascular Surgery, 1996, 111, 451-459. | 0.4 | 48 |

| # | Article | IF | Citations |
|---|---|---|---|
| 379 | Altered expression of host-encoded complement regulators on human cytomegalovirus-infected cells. European Journal of Immunology, 1996, 26, 1532-1538. | 1.6 | 71 |
| 380 | Expression of complement in the brain: role in health and disease. Trends in Immunology, 1996, 17, 461-466. | 7.5 | 219 |
| 381 | Expression and function of membrane regulators of complement on rat astrocytes in culture. Immunology, 1996, 88, 153-161. | 2.0 | 17 |
| 382 | Complement regulatory protein expression by a human oligodendrocyte cell line: cytokine regulation and comparison with astrocytes. Immunology, 1996, 89, 338-347. | 2.0 | 59 |
| 383 | Transfected CD59 protects mesangial cells from injury induced by antibody and complement. Kidney International, 1996, 50, 257-266. | 2.6 | 26 |
| 384 | Signalling through neutrophil Fc gamma RIII, Fc gamma RII, and CD59 is not impaired in active rheumatoid arthritis.. Annals of the Rheumatic Diseases, 1996, 55, 294-297. | 0.5 | 3 |
| 385 | The Effect of Soluble Complement Receptor 1 (sCR1) and Human Thyroid Antibodies on the Course of Experimental Autoimmune Thyroiditis in Rats. Autoimmunity, 1996, 23, 1-8. | 1.2 | 7 |
| 386 | Local inflammation caused by a monoclonal antibody that blocks the function of the rat membrane inhibitor of C3 convertase. Journal of Immunology, 1996, 156, 1182-8. | 0.4 | 12 |
| 387 | Identification and characterization of complement C3 receptors on human astrocytes. Journal of Immunology, 1996, 156, 2247-55. | 0.4 | 75 |
| 388 | Enhanced complement susceptibility of avidin-biotin-treated human erythrocytes is a consequence of neutralization of the complement regulators CD59 and decay accelerating factor. Biochemical Journal, 1995, 307, 651-656. | 1.7 | 42 |
| 389 | EXOGENOUS CD59 INCORPORATED INTO U937 CELLS THROUGH ITS GLYCOSYL PHOSPHATIDYLINOSITOL ANCHOR BECOMES ASSOCIATED WITH SIGNALLING MOLECULES IN A TIME DEPENDENT MANNER. Biochemical Society Transactions, 1995, 23, 269S-269S. | 1.6 | 5 |
| 390 | Evidence for activation of the terminal pathway of complement and upregulation of sulfated glycoprotein (SGP)-2 in the hypoglossal nucleus following peripheral nerve injury. Molecular and Chemical Neuropathology, 1995, 24, 53-68. | 1.0 | 48 |
| 391 | Complement regulation in the rat glomerulus: Crry and CD59 regulate complement in glomerular mesangial and endothelial cells. Kidney International, 1995, 48, 412-421. | 2.6 | 47 |
| 392 | Complement regulatory molecules: application to therapy and transplantation. Trends in Immunology, 1995, 16, 257-259. | 7.5 | 64 |
| 393 | Exogenous glycosyl phosphatidylinositol-anchored CD59 associates with kinases in membrane clusters on U937 cells and becomes Ca(2+)-signaling competent.. Journal of Cell Biology, 1995, 131, 669-677. | 2.3 | 138 |
| 394 | A functional role for corpora amylacea based on evidence from complement studies. Experimental Neurology, 1995, 4, 335-345. | 1.7 | 38 |
| 395 | A rapid method for the isolation of analogues of human CD59 by preparative SDS-PAGE: application to pig CD59. Journal of Immunological Methods, 1995, 179, 223-231. | 0.6 | 20 |
| 396 | Physiology and Pathophysiology of Complement: Progress and Trends. Critical Reviews in Clinical Laboratory Sciences, 1995, 32, 265-298. | 2.7 | 122 |

| # | Article | IF | Citations |
|---|---|---|---|
| 397 | Complement and clusterin in the spinal cord dorsal horn and gracile nucleus following sciatic nerve injury in the adult rat. Neuroscience, 1995, 68, 167-179. | 1.1 | 85 |
| 398 | Tubulointerstitial injury induced in rats by a monoclonal antibody that inhibits function of a membrane inhibitor of complement.. Journal of Clinical Investigation, 1995, 96, 2348-2356. | 3.9 | 75 |
| 399 | Reperfusion injury after myocardial infarction. BMJ: British Medical Journal, 1995, 310, 1411-1411. | 2.4 | 2 |
| 400 | Characterization of a glycosyl-phosphatidylinositol anchor-deficient subline of Raji cells. An analysis of the functional importance of complement inhibitors on the Raji cell line. Immunology, 1995, 86, 311-8. | 2.0 | 10 |
| 401 | Regulation of CD59 expression on K562 cells: effects of phorbol myristate acetate, cross-linking antibody and non-lethal complement attack. Immunology, 1995, 85, 146-52. | 2.0 | 16 |
| 402 | Apoptosis is associated with reduced expression of complement regulatory molecules, adhesion molecules and other receptors on polymorphonuclear leucocytes: functional relevance and role in inflammation. Immunology, 1995, 86, 651-60. | 2.0 | 79 |
| 403 | Crry and CD59 regulate complement in rat glomerular epithelial cells and are inhibited by the nephritogenic antibody of passive Heymann nephritis. Journal of Immunology, 1995, 154, 3437-43. | 0.4 | 40 |
| 404 | Complement expression in human brain. Biosynthesis of terminal pathway components and regulators in human glial cells and cell lines. Journal of Immunology, 1995, 154, 4726-33. | 0.4 | 177 |
| 405 | Identification and characterization of the complement C5a anaphylatoxin receptor on human astrocytes. Journal of Immunology, 1995, 155, 4882-9. | 0.4 | 125 |
| 406 | Complement membrane attack complex, perforin, and bacterial exotoxins induce in K562 cells calcium-dependent cross-protection from lysis. Journal of Immunology, 1995, 155, 2203-10. | 0.4 | 46 |
| 407 | In vivo effects of monoclonal antibodies that functionally inhibit complement regulatory proteins in rats.. Journal of Experimental Medicine, 1994, 180, 1619-1627. | 4.2 | 80 |
| 408 | Membrane proteins that protect against complement lysis. Seminars in Immunopathology, 1994, 15, 369-396. | 4.0 | 234 |
| 409 | The role of vasopressors in the management of hypotension induced by spinal and epidural anaesthesia. Canadian Journal of Anaesthesia, 1994, 41, 404-413. | 0.7 | 80 |
| 410 | Role of CD59 in experimental glomerulonephritis in rats. Kidney International, 1994, 46, 191-200. | 2.6 | 50 |
| 411 | Clinical complementology: recent progress and future trends. European Journal of Clinical Investigation, 1994, 24, 219-228. | 1.7 | 49 |
| 412 | The Distribution of Inflammatory Demyelinated Lesions in the Central Nervous System of Rats with Antibody-Augmented Demyelinating Experimental Allergic Encephalomyelitis. Experimental Neurology, 1994, 129, 299-310. | 2.0 | 28 |
| 413 | EXPRESSION OF COMPLEMENT REGULATORY MOLECULES AND OTHER SURFACE MARKERS ON NEUTROPHILS FROM SYNOVIAL FLUID AND BLOOD OF PATIENTS WITH RHEUMATOID ARTHRITIS. Rheumatology, 1994, 33, 707-712. | 0.9 | 35 |
| 414 | Human Cell-Adhesion Molecule CD2 Binds CD58 (LFA-3) with a Very Low Affinity and an Extremely Fast Dissociation Rate but Does Not Bind CD48 or CD59. Biochemistry, 1994, 33, 10149-10160. | 1.2 | 198 |

| # | Article | IF | Citations |
|---|---|---|---|
| 415 | Molecular cloning of the rat analogue of human CD59: structural comparison with human CD59 and identification of a putative active site. Biochemical Journal, 1994, 304, 595-601. | 1.7 | 70 |
| 416 | Comparative susceptibility of peripheral blood leucocytes and related cell lines to killing by T-cell perforin. Immunology, 1994, 82, 555-60. | 2.0 | 1 |
| 417 | Tissue distribution of complement regulatory membrane proteins in rats. Immunology, 1994, 81, 444-51. | 2.0 | 68 |
| 418 | Expression and function of multiple regulators of complement activation in autoimmune thyroid disease. Immunology, 1994, 81, 643-7. | 2.0 | 35 |
| 419 | Presence of a dysfunctional form of CD59 on a CD59+ subclone of the U937 cell line. Immunology, 1994, 81, 637-42. | 2.0 | 7 |
| 420 | Time course of complement activation and inhibitor expression after ischemic injury of rat myocardium. American Journal of Pathology, 1994, 144, 1357-68. | 1.9 | 86 |
| 421 | Complement-inhibiting activities of human CD59 and analogues from rat, sheep, and pig are not homologously restricted. Journal of Immunology, 1994, 152, 4095-101. | 0.4 | 62 |
| 422 | Soluble recombinant complement receptor 1 inhibits inflammation and demyelination in antibody-mediated demyelinating experimental allergic encephalomyelitis. Journal of Immunology, 1994, 152, 5477-84. | 0.4 | 150 |
| 423 | Cross-linking of CD59 and of other glycosyl phosphatidylinositol-anchored molecules on neutrophils triggers cell activation via tyrosine kinase. European Journal of Immunology, 1993, 23, 2841-2850. | 1.6 | 97 |
| 424 | Killing of rat glial cells by complement: Deficiency of the rat analogue of CD59 is the cause of oligodendrocyte susceptibility to lysis. Journal of Neuroimmunology, 1993, 48, 169-175. | 1.1 | 56 |
| 425 | Physiologic relevance of the membrane attack complex inhibitory protein CD59 in human seminal plasma: CD59 is present on extracellular organelles (prostasomes), binds cell membranes, and inhibits complement-mediated lysis.. Journal of Experimental Medicine, 1993, 177, 1409-1420. | 4.2 | 192 |
| 426 | Expression of the glycosylphosphatidylinositol-linked complement-inhibiting protein CD59 antigen in insect cells using a baculovirus vector. Biochemical Journal, 1993, 295, 889-896. | 1.7 | 38 |
| 427 | Cellular responses to the membrane attack complex. , 1993, , 325-351. | | 6 |
| 428 | Complement in diseases of the nervous system. , 1993, , 353-375. | | 10 |
| 429 | The sheep analogue of human CD59: purification and characterization of its complement inhibitory activity. Immunology, 1993, 78, 349-57. | 2.0 | 29 |
| 430 | Immunolocalization and characterization of the rat analogue of human CD59 in kidney and glomerular cells. Immunology, 1993, 80, 439-44. | 2.0 | 13 |
| 431 | The demyelinating potential of antibodies to myelin oligodendrocyte glycoprotein is related to their ability to fix complement. American Journal of Pathology, 1993, 143, 555-64. | 1.9 | 225 |
| 432 | Isolation and characterization of the complement-inhibiting protein CD59 antigen from platelet membranes. Biochemical Journal, 1992, 282, 409-413. | 1.7 | 49 |

| # | Article | IF | Citations |
|---|---|---|---|
| 433 | Isolation and characterization of a membrane protein from rat erythrocytes which inhibits lysis by the membrane attack complex of rat complement. Biochemical Journal, 1992, 284, 169-176. | 1.7 | 83 |
| 434 | Meningococcal septicaemia in a C6-deficient patient and effects of plasma transfusion on lipopolysaccharide release. Lancet, The, 1992, 340, 1379-1381. | 6.3 | 77 |
| 435 | The role of calcium in rat oligodendrocyte injury and repair. Neuroscience Letters, 1992, 135, 95-98. | 1.0 | 34 |
| 436 | Antithyroid drugs and release of inflammatory mediators by complement-attacked thyroid cells. Lancet, The, 1992, 340, 633-636. | 6.3 | 85 |
| 437 | Effects of the Membrane Attack Complex of Complement on Nucleated Cells. Current Topics in Microbiology and Immunology, 1992, 178, 115-140. | 0.7 | 106 |
| 438 | Expression and function of membrane attack complex inhibitory proteins on thyroid follicular cells. Immunology, 1992, 75, 372-7. | 2.0 | 34 |
| 439 | Membrane attack complex (MAC)-mediated damage to spermatozoa: protection of the cells by the presence on their membranes of MAC inhibitory proteins. Immunology, 1992, 75, 499-506. | 2.0 | 52 |
| 440 | Properties of a low molecular weight complement component C6 found in human subjects with subtotal C6 deficiency. Immunology, 1992, 75, 10-6. | 2.0 | 29 |
| 441 | Characterization of the membrane attack complex inhibitory protein CD59 antigen on human amniotic cells and in amniotic fluid. Immunology, 1992, 76, 541-7. | 2.0 | 54 |
| 442 | Immunohistochemical determination of complement activation in joint tissues of patients with rheumatoid arthritis and osteoarthritis using neoantigen-specific monoclonal antibodies. Journal of Clinical & Laboratory Immunology, 1992, 37, 147-62. | 0.1 | 35 |
| 443 | Killing of cells by perforin. Resistance to killing is not due to diminished binding of perforin to the cell membrane. Biochemical Journal, 1991, 280, 199-204. | 1.7 | 13 |
| 444 | Complement deficiency and disease. Trends in Immunology, 1991, 12, 301-306. | 7.5 | 282 |
| 445 | Imaging Ca2+ changes in individual oligodendrocytes attacked by T-cell perforin. Immunology, 1991, 74, 572-7. | 2.0 | 14 |
| 446 | Terminal complement complexes and C1/C1 inhibitor complexes in rheumatoid arthritis and other arthritic conditions. Clinical and Experimental Immunology, 1991, 84, 250-5. | 1.1 | 21 |
| 447 | Non-lethal doses of antibody and complement stimulate release of prostaglandin E2 from human amniotic cells in vitro. Biochemical Society Transactions, 1990, 18, 617-617. | 1.6 | 6 |
| 448 | Isolation and characterization of a membrane-attack-complex-inhibiting protein present in human serum and other biological fluids. Biochemical Journal, 1990, 265, 471-477. | 1.7 | 64 |
| 449 | Reversible cell damage by T-cell perforins. Calcium influx and propidium iodide uptake into K562 cells in the absence of lysis. Biochemical Journal, 1990, 267, 303-307. | 1.7 | 38 |
| 450 | Presence of a membrane attack complex inhibiting protein on the human epithelial cell line HeLa. Biochemical Society Transactions, 1990, 18, 673-674. | 1.6 | 6 |

| # | Article | IF | Citations |
|---|---|---|---|
| 451 | Transience of membrane channels induced by perforin and by the membrane attack complex. Biochemical Society Transactions, 1990, 18, 674-675. | 1.6 | 0 |
| 452 | Purification of C8 and C9 from Rat Serum. Complement and Inflammation, 1990, 7, 42-51. | 0.8 | 26 |
| 453 | Human protectin (CD59), an 18-20-kD homologous complement restriction factor, does not restrict perforin-mediated lysis.. Journal of Experimental Medicine, 1990, 172, 367-370. | 4.2 | 55 |
| 454 | Complement mediated serum cytotoxicity against oligodendrocytes: a comparison with other cells of the oligodendrocyte-type 2 astrocyte lineage. Journal of the Neurological Sciences, 1990, 97, 155-162. | 0.3 | 22 |
| 455 | Oligodendrocyte susceptibility to injury by T-cell perforin. Immunology, 1990, 70, 6-10. | 2.0 | 52 |
| 456 | Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology, 1990, 71, 1-9. | 2.0 | 419 |
| 457 | Protection of human amniotic epithelial cells (HAEC) from complement-mediated lysis: expression on the cells of three complement inhibitory membrane proteins. Immunology, 1990, 71, 308-11. | 2.0 | 22 |
| 458 | Human rheumatoid synovial cell stimulation by the membrane attack complex and other pore-forming toxins in vitro: the role of calcium in cell activation. Immunology, 1990, 71, 312-6. | 2.0 | 14 |
| 459 | Stimulation of human rheumatoid synovial cells by non-lethal complement membrane attack. Immunology, 1990, 69, 237-42. | 2.0 | 35 |
| 460 | Mechanisms of Tissue Damage by the Membrane Attack Complex of Complement. Complement and Inflammation, 1989, 6, 104-111. | 0.8 | 37 |
| 461 | THE ROLE OF COMPLEMENT IN THE PATHOGENESIS OF EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS. Brain, 1989, 112, 895-911. | 3.7 | 156 |
| 462 | Complement membrane attack on nucleated cells: resistance, recovery and non-lethal effects. Biochemical Journal, 1989, 264, 1-14. | 1.7 | 359 |
| 463 | IMMUNOCYTOCHEMICAL LOCALIZATION OF THE TERMINAL COMPLEMENT COMPLEX IN MULTIPLE SCLEROSIS. Neuropathology and Applied Neurobiology, 1989, 15, 307-316. | 1.8 | 169 |
| 464 | Photoproteins as indicators of intracellular free Ca2+. Luminescence, 1989, 4, 463-474. | 1.3 | 14 |
| 465 | Immunohistochemical localisation of terminal complement component C9 in experimental allergic encephalomyelitis. Acta Neuropathologica, 1989, 79, 78-85. | 3.9 | 58 |
| 466 | Vesicular removal by oligodendrocytes of membrane attack complexes formed by activated complement. Nature, 1989, 339, 620-622. | 13.7 | 237 |
| 467 | Myelin-oligodendrocyte glycoprotein (MOG) is a surface marker of oligodendrocyte maturation. Journal of Neuroimmunology, 1989, 22, 169-176. | 1.1 | 119 |
| 468 | Normal rat serum cytotoxicity against syngeneic oligodendrocytes. Journal of the Neurological Sciences, 1989, 89, 289-300. | 0.3 | 113 |

| # | Article | IF | Citations |
|---|---|---|---|
| 469 | Killing of gram-negative bacteria by complement. Fractionation of cell membranes after complement C5b-9 deposition on to the surface of Salmonella minnesota Re595. Biochemical Journal, 1989, 263, 505-511. | 1.7 | 26 |
| 470 | Presence of a membrane attack complex inhibiting protein in biological fluids. Biochemical Society Transactions, 1989, 17, 725-726. | 1.6 | 0 |
| 471 | Purification of S protein (vitronectin) by a one-step immunoaffinity chromatography procedure. Biochemical Society Transactions, 1989, 17, 726-727. | 1.6 | 1 |
| 472 | Activation of human synoviocytes by sub-lytic complement attack. Biochemical Society Transactions, 1989, 17, 724-725. | 1.6 | 0 |
| 473 | Reversible injury of cultured rat oligodendrocytes by complement. Immunology, 1989, 67, 441-6. | 2.0 | 42 |
| 474 | Terminal complement complexes and C1/C1 inhibitor complexes in autoimmune thyroid disease. Clinical and Experimental Immunology, 1989, 77, 25-30. | 1.1 | 39 |
| 475 | A case of hereditary combined deficiency of complement components C6 and C7 in man. Clinical and Experimental Immunology, 1989, 75, 396-401. | 1.1 | 27 |
| 476 | The preparation and characterization of monoclonal antibodies to human complement component C8 and their use in purification of C8 and C8 subunits. Biochemical Journal, 1988, 251, 285-292. | 1.7 | 35 |
| 477 | Non-lethal complement-membrane attack on human neutrophils: transient cell swelling and metabolic depletion. Immunology, 1988, 63, 71-7. | 2.0 | 15 |
| 478 | Measurement of terminal complement complexes in rheumatoid arthritis. Clinical and Experimental Immunology, 1988, 73, 473-8. | 1.1 | 62 |
| 479 | In vivo and in vitro evidence of cell recovery from complement attack in rheumatoid synovium. Clinical and Experimental Immunology, 1988, 73, 467-72. | 1.1 | 27 |
| 480 | A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 2. Laboratory results.. Journal of Neurology, Neurosurgery and Psychiatry, 1987, 50, 517-522. | 0.9 | 51 |
| 481 | The ring-like classical complement lesion is not the functional pore of the membrane attack complex. Biochemical Society Transactions, 1987, 15, 659-660. | 1.6 | 1 |
| 482 | Role of complement C9 and calcium in the generation of arachidonic acid and its metabolites from rat polymorphonuclear leukocytesâ¯†. Molecular Immunology, 1987, 24, 1263-1271. | 1.0 | 17 |
| 483 | Cerebrospinal Fluid Complement Components in Multiple Sclerosis. , 1987, , 201-209. | | 1 |
| 484 | Complement-Mediated Plasma-Membrane Damage: Effects on Cell Physiology, Prospects of Cell Recovery and Implications for Disease Mechanisms. , 1987, , 199-209. | | 0 |
| 485 | Recovery of human neutrophils from complement attack: removal of the membrane attack complex by endocytosis and exocytosis. Journal of Immunology, 1987, 138, 246-53. | 0.4 | 197 |
| 486 | COMPLEMENT COMPONENT C9 IN GRAVES' DISEASE. Clinical Endocrinology, 1986, 25, 623-632. | 1.2 | 13 |

| # | Article | IF | Citations |
|---|---|---|---|
| 487 | Intracellular Ca2+ and cell injury: A paradoxical role of Ca2+ in complement membrane attack. Cell Calcium, 1986, 7, 399-411. | 1.1 | 106 |
| 488 | THE NINTH COMPLEMENT COMPONENT IN RHEUMATOID ARTHRITIS, BEHÃ‡ET'S DISEASE AND OTHER RHEUMATIC DISEASES. Rheumatology, 1986, 25, 266-270. | 0.9 | 19 |
| 489 | Cerebrospinal fluid C9 in demyelinating disease. Neurology, 1986, 36, 1503-1503. | 1.5 | 46 |
| 490 | Complement lysis of U937, a nucleated mammalian cell line in the absence of C9: effect of C9 on C5b-8 mediated cell lysis. Journal of Immunology, 1986, 136, 3402-6. | 0.4 | 28 |
| 491 | The recovery of human polymorphonuclear leucocytes from sublytic complement attack is mediated by changes in intracellular free calcium. Biochemical Journal, 1985, 231, 205-208. | 1.7 | 139 |
| 492 | Monoclonal antibodies and the structure of complement component C9. Biochemical Society Transactions, 1985, 13, 105-106. | 1.6 | 0 |
| 493 | Monoclonal antibodies demonstrate protection of polymorphonuclear leukocytes against complement attack. Nature, 1985, 317, 164-166. | 13.7 | 118 |
| 494 | Measurement of C9 concentrations using an immunochemiluminometric assay. Journal of Immunological Methods, 1985, 80, 33-38. | 0.6 | 12 |
| 495 | 2-Chloroadenosine inhibits complement-induced reactive oxygen metabolite production and recovery of human polymorphonuclear leucocytes attacked by complement. Biochemical and Biophysical Research Communications, 1985, 126, 692-697. | 1.0 | 34 |
| 496 | Use of Polyclonal and Monoclonal Antibodies in Studying Complement Component C9 as a Trans-Membrane Protein. , 1985, , 247-253. | | 1 |
| 497 | TERMINAL COMPONENT OF COMPLEMENT (C9) IN CEREBROSPINAL FLUID OF PATIENTS WITH MULTIPLE SCLEROSIS. Lancet, The, 1984, 324, 251-255. | 6.3 | 76 |
| 498 | Inhibition of complement-induced [14C]sucrose release by intracellular and extracellular monoclonal antibodies to C9: Evidence that C9 is a transmembrane protein. Biochemical and Biophysical Research Communications, 1984, 118, 616-622. | 1.0 | 32 |
| 499 | Recovery of polymorphonuclear leucocytes from complement attack. Biochemical Society Transactions, 1984, 12, 779-780. | 1.6 | 18 |
| 500 | Immunolocalization of complement component C9 on necrotic and non-necrotic muscle fibres in myositis using monoclonal antibodies: a primary role of complement in autoimmune cell damage. Immunology, 1984, 52, 181-8. | 2.0 | 31 |
| 501 | Immunoaffinity purification of human complement component C9 using monoclonal antibodies. Journal of Immunological Methods, 1983, 64, 269-281. | 0.6 | 64 |
| 502 | Immunoradiometric assay for human complement component C9 utilising monoclonal antibodies. Clinica Chimica Acta, 1983, 134, 85-94. | 0.5 | 15 |
| 503 | Complement-mediated lysis of pigeon erythrocyte ghosts analysed by flow cytometry. Evidence for the involvement of a â€˜thresholdâ€™ phenomenon. Biochemical Journal, 1983, 216, 195-202. | 1.7 | 20 |
| 504 | Complement Regulation and the Host Response to Infection. , 0, , 159-174. | | 0 |